Informatie:
Fout:
ID
34184
Beschrijving
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention; ODM derived from: https://clinicaltrials.gov/show/NCT01442792
Link
https://clinicaltrials.gov/show/NCT01442792
Trefwoorden
Versies (1)
- 15-01-19 15-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
15 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Cardiovascular Disease, Coronary Artery Disease NCT01442792
Eligibility Cardiovascular Disease, Coronary Artery Disease NCT01442792
- StudyEvent: Eligibility
Similar models
Eligibility Cardiovascular Disease, Coronary Artery Disease NCT01442792
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
male or female subject aged 18 years or more with no upper age limit and willing to comply with the protocol
boolean
ID.2
Item
symptomatic coronary artery disease due to undergo an elective (non-emergent) percutaneous coronary intervention (pci) on one or two lesions in the native coronary vessel(s). cardiac standard troponin at baseline is within the normal limits
boolean
ID.3
Item
conditions that may increase the risk of the pci procedure
boolean
ID.4
Item
conditions that may increase the risk of bleeding
boolean
ID.5
Item
significant valvular heart disease
boolean
ID.6
Item
calculated creatinine clearance ≤30 ml/min
boolean
ID.7
Item
current use of anticoagulant drugs including vitamin k antagonist (vka), factor iia or factor xa inhibitors
boolean
ID.8
Item
chronic treatment with non-steroidal anti-inflammatory drugs (nsaids)
boolean
ID.9
Item
chronic treatment with aspirin > 100mg
boolean